Literature DB >> 33844864

Daratumumab, lenalidomide, and dexamethasone in systemic light-chain amyloidosis: High efficacy, relevant toxicity and main adverse effect of gain 1q21.

Christoph R Kimmich1,2,3, Tobias Terzer4, Axel Benner4, Timon Hansen5, Alexander Carpinteiro6, Tobias Dittrich1,2, Kaya Veelken1,2, Anna Jauch7, Stefanie Huhn1, Marco Basset1,2,8,9, Hartmut Goldschmidt1,10, Carsten Müller-Tidow1, Stefan O Schönland1,2, Ute Hegenbart1,2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2021        PMID： 33844864     DOI： 10.1002/ajh.26191

Source DB:  PubMed          Journal:  Am J Hematol        ISSN： 0361-8609            Impact factor:   10.047


× No keyword cloud information.
  3 in total

Review 1.  Efficacy and safety of intravenous daratumumab-based treatments for AL amyloidosis: a systematic review and meta-analysis.

Authors:  Chunyan Sun; Xiaohong Wang; Renyi Zhang; Lingjie Xu; Bin Wang; Jian Li
Journal:  Cancer Cell Int       Date:  2022-07-04       Impact factor: 6.429

2.  Analysis of the complete lambda light chain germline usage in patients with AL amyloidosis and dominant heart or kidney involvement.

Authors:  Natalie Berghaus; Sarah Schreiner; Martin Granzow; Carsten Müller-Tidow; Ute Hegenbart; Stefan O Schönland; Stefanie Huhn
Journal:  PLoS One       Date:  2022-02-25       Impact factor: 3.240

Review 3.  Genetic pathogenesis of immunoglobulin light chain amyloidosis: basic characteristics and clinical applications.

Authors:  Linchun Xu; Yongzhong Su
Journal:  Exp Hematol Oncol       Date:  2021-07-20
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.